Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.

被引：0
|
作者：
Satake, Hironaga
Lee, Keun Wook
Chung, Hyun Cheol
Lee, Jeeyuan
Yamaguchi, Kensei
Chen, Jen-Shi
Yoshikawa, Takaki
Amagai, Kenji
Yeh, Kun-Huei
Goto, Masahiro
Chao, Yee
Lam, Ka-On
Han, Shi Rong
Shiratori, Shinichi
Shah, Sukrut
Shitara, Kohei
机构：
[1] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan
[2] Seoul Natl Univ, Coll Med, Bundang Hosp, Seongnam, South Korea
[3] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[4] Samsung Med Ctr, Seoul, South Korea
[5] Canc Inst Hosp JFCR, Tokyo, Japan
[6] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan
[7] Chang Gung Univ, Taoyuan, Taiwan
[8] Natl Canc Ctr, Tokyo, Japan
[9] Ibaraki Cent Hosp, Ibaraki, Japan
[10] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Osaka Med Coll Hosp, Osaka, Japan
[13] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan
[14] Queen Mary Hosp, Hong Kong, Peoples R China
[15] MSD KK, Tokyo, Japan
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4523
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
    Satake, Hironaga
    Lee, Keun-Wook
    Chung, Hyun Cheol
    Lee, Jeeyun
    Yamaguchi, Kensei
    Chen, Jen-Shi
    Yoshikawa, Takaki
    Amagai, Kenji
    Yeh, Kun-Huei
    Goto, Masahiro
    Chao, Yee
    Lam, Ka-On
    Han, Shi Rong
    Shiratori, Shinichi
    Shah, Sukrut
    Shitara, Kohei
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) : 221 - 229
  • [2] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
    Tabernero, Josep
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Salguero, Hugo Raul Castro
    Mansoor, Wasat
    Braghiroli, Maria Ignez Freitas Melro
    Goekkurt, Eray
    Chao, Joseph
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, SoonMo Peter
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [3] Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
    Oh, D-Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Li, J.
    Luo, S.
    Pan, H.
    Qu, Y.
    Lu, J.
    Yang, L.
    Yasui, H.
    Yabusaki, H.
    Yen, C. J.
    Chan, W. W. L.
    Yamaguchi, K.
    Yeh, K-H.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Rha, S. Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1526
  • [4] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
    Tabernero, J.
    Van Cussem, E.
    Bang, Y.
    Fuchs, C.
    Wyrwicz, L.
    Lee, K.
    Kudaba, I.
    Garrido, M.
    Chung, C.
    Salguero, C. Castro
    Mansoor, W.
    Braghiroli, M.
    Goekkurt, E.
    Chao, J.
    Wainberg, Z.
    Kher, U.
    Shah, S.
    Karg, S.
    Shitara, K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
  • [5] Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
    Wainberg, Zev A.
    Shitara, Kohei
    Van Cutsem, Eric
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol Cheol
    Lee, Jeeyun
    Castro-Salguero, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Goekkurt, Eray
    Satake, Hironaga
    Chao, Joseph
    Kher, Uma
    Shah, Sukrut
    Bhagia, Pooja
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [8] Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585
    Shitara, Kohei
    Bang, Yung-Jue
    Wyrwicz, Lucjan S.
    Rha, Sun Young
    Oshima, Takashi
    Di Bartolomeo, Maria
    Park, Young-Kyu
    Lonardi, Sara
    Weber, Patricio Eduardo Yanez
    Yen, Chia-Jui
    Metges, Jean-Philippe
    Garrido, Marcelo
    Moehler, Markus H.
    Pelles-Avraham, Sharon
    Yong, Wei-Peng
    Spallanzani, Andrea
    Jensen, Erin
    Krishnan, Radha
    Shih, Chie-Schin
    Al-Batran, Salah-Eddin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
    Rha, Sun Young
    Wyrwicz, Lucjan S.
    Weber, Patricio Eduardo Yanez
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve Aine
    Cil, Timucin
    Cruz, Felipe Melo
    Oh, Do-Youn
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Qin, Shukui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345